Phase II

Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.
Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
Arthritis Rheum. 2005 Dec 15;53(6):856-63.

Rudwaleit M, Baraliakos X, Listing J, Brandt J, Sieper J, Braun J
Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept.
Ann Rheum Dis. 2005;64(9):1305-10

Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T, King L, Davis JC Jr
Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis
J Rheumatol. 2005 Oct;32(10):1911-7

Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J.
Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis
Rheumatology (Oxford). 2005; 44(3):342-8

Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis
Arthritis Rheum 2003; 48: 1667-1675

Gorman JD, Sack KE, Davis JC Jr.
Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha
N Engl J Med. 2002; 346(18):1349-56